3446-72-8

Basic information

• Product Name: ETHYL 2-(5-CHLORO-2-METHYL-1H-INDOL-3-YL)ACETATE
• Synonyms: ETHYL 2-(5-CHLORO-2-METHYL-1H-INDOL-3-YL)ACETATE;(5-CHLORO-2-METHYL-1H-INDOL-3-YL)-ACETIC ACID ETHYL ESTER
• CAS NO: 3446-72-8
• Molecular Formula: C₁₃H₁₄ClNO₂
• Molecular Weight: 251.71
• Mol File: 3446-72-8.mol
• Article Data: 8

Chemical Properties

• Melting Point: 85 °C
• Boiling Point: 396.6±37.0 °C(Predicted)
• Appearance: /
• Density: 1.262±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 16.36±0.30(Predicted)
• CAS DataBase Reference: ETHYL 2-(5-CHLORO-2-METHYL-1H-INDOL-3-YL)ACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-(5-CHLORO-2-METHYL-1H-INDOL-3-YL)ACETATE(3446-72-8)
• EPA Substance Registry System: ETHYL 2-(5-CHLORO-2-METHYL-1H-INDOL-3-YL)ACETATE(3446-72-8)

Safety Data

• Hazardous Substances Data: 3446-72-8(Hazardous Substances Data)

Usage

General Description

ETHYL 2-(5-CHLORO-2-METHYL-1H-INDOL-3-YL)ACETATE is a chemical compound with the molecular formula C13H14ClNO2. It is a derivative of indole, which is a heterocyclic aromatic organic compound. This chemical is commonly used in the pharmaceutical industry as an intermediate for the synthesis of various drugs, including anti-inflammatory and anti-cancer medications. It has a pale yellow color and is soluble in organic solvents such as ethanol and diethyl ether. Its structure contains a chloro-methyl-indole ring attached to an ethyl acetate group, giving it potential medicinal and industrial applications.

Upstream product

• 539-88-8 4-oxopentanoic acid ethyl ester 
• 1073-69-4 N-4-chlorophenylhydrazine 
• 57335-86-1 5-Chloro-2-methyl-1H-indole-3-carboxaldehyde 
• 1073-70-7 4-chlorophenylhydrazine hydrochloride 
• 64-17-5 ethanol 
• 19017-52-8 2-(5-chloro-2-methyl-1H-indol-3-yl)acetic acid 

Downstream Products

• 479422-76-9 methyl 3-[4-[[2-[5-chloro-1-(diphenylmethyl)-2-methyl-1H-indol-3-yl]ethyl]sulfonyl]phenyl]propanoate 
• 872674-81-2 methyl 4-[4-[2-[5-chloro-1-(diphenylmethyl)-2-methyl-1H-indol-3-yl]ethoxy]phenyl]butanoate 
• 479422-75-8 methyl 3-[4-[[2-[5-chloro-1-(diphenylmethyl)-2-methyl-1H-indol-3-yl]ethyl]thio]phenyl]propanoate 
• 872674-83-4 methyl 2-chloro-4-[2-[5-chloro-1-(diphenylmethyl)-2-methyl-1H-indol-3-yl]ethoxy]benzoate 
• 872674-85-6 methyl 4-[2-[5-chloro-1-(diphenylmethyl)-2-methyl-1H-indol-3-yl]ethoxy]-2-fluorobenzoate 
• 923584-42-3 methyl 3-chloro-4-[2-[5-chloro-1-(diphenylmethyl)-2-methyl-1H-indol-3-yl]ethoxy]benzoate 
• 479422-79-2 methyl 3-[4-[2-[5-chloro-1-(diphenylmethyl)-2-methyl-1H-indol-3-yl]ethoxy]phenyl]propanoate 
• 872674-75-4 methyl 4-[[2-[5-chloro-1-(diphenylmethyl)-2-methyl-1H-indol-3-yl]ethyl]amino]benzoate 
• 872674-79-8 methyl [4-[2-[5-chloro-1-(diphenylmethyl)-2-methyl-1H-indol-3-yl]ethoxy]phenyl]acetate 

Relevant articles and documents

Indole compounds with: N-ethyl morpholine moieties as CB2 receptor agonists for anti-inflammatory management of pain: Synthesis and biological evaluation

The CB2 receptor plays a crucial role in analgesia and anti-inflammation. To develop novel CB2 agonists with high efficacy and selectivity, a series of indole derivatives with N-ethyl morpholine moieties (compounds 1-56) were designed, synthesized and biologically evaluated. Compounds 1, 2, 3, 46 and 53 exhibited high CB2 receptor affinity at low nanomolar concentrations and good receptor selectivity (EC50(CB1)/EC50(CB2) greater than 1000). The most active compound, compound 2, was more potent than the standard drug GW405833 for in vitro agonistic action on the CB2 receptor. More importantly, in a rat model for CFA-induced inflammatory hyperalgesia, compound 2 had a potent anti-inflammatory pain effect within 12 hours after administration. At the 1 h time point, compound 2 had a dose-dependent reversal for hyperalgesia with an estimated ED50 value of 1.097 mg kg-1. Moreover, compound 2 significantly suppressed the pro-inflammatory cytokines (IL-1β, IL-6 and TNF-α) in CFA-induced lesions. These protective effects of compound 2 on inflammatory pain were superior to those of GW405833, suggesting that compound 2 may be a promising therapeutic drug that needs further validation.

Hypoglycemic imidazoline compounds

This invention relates to certain novel imidazoline compounds and analogues thereof, to their use for the treatment of diabetes, diabetic complications, metabolic disorders, or related diseases where impaired glucose disposal is present, to pharmaceutical compositions comprising them, and to processes for their preparation.

Hypoglycemic imidazoline compounds

This invention relates to certain novel imidazoline compounds and analogues thereof, to their use for the treatment of diabetes, diabetic complications, metabolic disorders, or related diseases where impaired glucose disposal is present, to pharmaceutical compositions comprising them, and to processes for their preparation.